COVID-19 drug trial halted: did INB03 help High-Risk patients avoid ICU?

NCT ID NCT04370236

Terminated Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated Jun 12, 2026 · Updated 5 times

Summary

This study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could stop their lung problems from getting worse. Participants had conditions like older age, obesity, or heart disease. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID 19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Baptist Clinical Research Institute

Memphis, Tennessee, 38120, United States
Baptist Memorial Hospital-DeSoto

Southard, Missouri, 38671, United States
Jewish Hospital

Louisville, Kentucky, 40202, United States
Memorial Hermann

Houston, Texas, 77030, United States
Memorial Hermann Southeast

Houston, Texas, 77089, United States
Mississippi Baptist

Kosciusko, Mississippi, 39090, United States
NEA Baptist

Jonesboro, Arkansas, 72401, United States
Richmond University Medical Center

Staten Island, New York, 10312, United States
St. Bernard's

Jonesboro, Arkansas, 72401, United States

Conditions

The condition(s) this trial relates to.

COVID-19 cytokine release syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID 19